BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sousa I, Rodrigues F, Prazeres H, Lima RT, Soares P. Liposomal therapies in oncology: does one size fit all? Cancer Chemother Pharmacol 2018;82:741-55. [DOI: 10.1007/s00280-018-3668-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Gonçalves Lopes RCF, Silvestre OF, Faria AR, C do Vale ML, Marques EF, Nieder JB. Surface charge tunable catanionic vesicles based on serine-derived surfactants as efficient nanocarriers for the delivery of the anticancer drug doxorubicin. Nanoscale 2019;11:5932-41. [PMID: 30556563 DOI: 10.1039/c8nr06346j] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 5.3] [Reference Citation Analysis]
2 Yellepeddi VK, Joseph A, Nance E. Pharmacokinetics of nanotechnology-based formulations in pediatric populations. Adv Drug Deliv Rev 2019;151-152:44-55. [PMID: 31494124 DOI: 10.1016/j.addr.2019.08.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
3 Príncipe C, Dionísio de Sousa IJ, Prazeres H, Soares P, Lima RT. LRP1B: A Giant Lost in Cancer Translation. Pharmaceuticals (Basel) 2021;14:836. [PMID: 34577535 DOI: 10.3390/ph14090836] [Reference Citation Analysis]
4 Cheng CT, Castro G, Liu CH, Lau P. Advanced nanotechnology: An arsenal to enhance immunotherapy in fighting cancer. Clin Chim Acta 2019;492:12-9. [PMID: 30711524 DOI: 10.1016/j.cca.2019.01.027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
5 Pastorino F, Brignole C, Di Paolo D, Perri P, Curnis F, Corti A, Ponzoni M. Overcoming Biological Barriers in Neuroblastoma Therapy: The Vascular Targeting Approach with Liposomal Drug Nanocarriers. Small 2019;15:1804591. [DOI: 10.1002/smll.201804591] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
6 Ong YR, De Rose R, Johnston APR. In Vivo Quantification of Nanoparticle Association with Immune Cell Subsets in Blood. Adv Healthc Mater 2021;10:e2002160. [PMID: 33644997 DOI: 10.1002/adhm.202002160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Filip S, Kubeček O, Špaček J, Lánská M, Bláha M. Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years. Pharmaceutics. 2020;12. [PMID: 33008072 DOI: 10.3390/pharmaceutics12100940] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Alessandri G, Pessina A, Paroni R, Bercich L, Paino F, Dei Cas M, Cadei M, Caruso A, Schiariti M, Restelli F, Zeira O, Tremolada C, Portolani N. Single-Shot Local Injection of Microfragmented Fat Tissue Loaded with Paclitaxel Induces Potent Growth Inhibition of Hepatocellular Carcinoma in Nude Mice. Cancers (Basel) 2021;13:5505. [PMID: 34771667 DOI: 10.3390/cancers13215505] [Reference Citation Analysis]
9 Meng Y, Han S, Gu Z, Wu J. Cysteine‐Based Biomaterials as Drug Nanocarriers. Adv Therap 2020;3:1900142. [DOI: 10.1002/adtp.201900142] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
10 Banerjee D, Cieslar-Pobuda A, Zhu GH, Wiechec E, Patra HK. Adding Nanotechnology to the Metastasis Treatment Arsenal. Trends Pharmacol Sci 2019;40:403-18. [PMID: 31076247 DOI: 10.1016/j.tips.2019.04.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
11 Alessandri G, Coccè V, Pastorino F, Paroni R, Dei Cas M, Restelli F, Pollo B, Gatti L, Tremolada C, Berenzi A, Parati E, Brini AT, Bondiolotti G, Ponzoni M, Pessina A. Microfragmented human fat tissue is a natural scaffold for drug delivery: Potential application in cancer chemotherapy. Journal of Controlled Release 2019;302:2-18. [DOI: 10.1016/j.jconrel.2019.03.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
12 Pereira SGT, Hudoklin S, Kreft ME, Kostevsek N, Stuart MCA, Al-jamal WT. Intracellular Activation of a Prostate Specific Antigen-Cleavable Doxorubicin Prodrug: A Key Feature Toward Prodrug-Nanomedicine Design. Mol Pharmaceutics 2019;16:1573-85. [DOI: 10.1021/acs.molpharmaceut.8b01257] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
13 Pan DC, Krishnan V, Salinas AK, Kim J, Sun T, Ravid S, Peng K, Wu D, Nurunnabi M, Nelson JA, Niziolek Z, Guo J, Mitragotri S. Hyaluronic acid-doxorubicin nanoparticles for targeted treatment of colorectal cancer. Bioeng Transl Med 2021;6:e10166. [PMID: 33532580 DOI: 10.1002/btm2.10166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Das M, Huang L. Liposomal Nanostructures for Drug Delivery in Gastrointestinal Cancers. J Pharmacol Exp Ther 2019;370:647-56. [PMID: 30541917 DOI: 10.1124/jpet.118.254797] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]